What is the recommended pneumococcal vaccination schedule for adults, including those ≥ 65 years, adults 19‑64 with high‑risk medical conditions, and immunocompromised patients?

Pneumococcal Vaccination Schedule for Adults

Primary Recommendation

All adults aged ≥50 years should receive a single dose of pneumococcal conjugate vaccine (PCV20, PCV21, or PCV15 followed by PPSV23) if they have never received a PCV or their vaccination history is unknown. 1, 2, 3

---

Age-Based Recommendations

Adults ≥65 Years (No Immunocompromising Conditions)

Option A (Preferred for simplicity):

• Single dose of PCV20 or PCV21 1, 2

Option B:

• PCV15 followed by PPSV23 ≥1 year later 1

If previously vaccinated:

• PPSV23 only → Give PCV20/PCV21 or PCV15 after ≥1 year interval 1
• PCV13 only → Give PCV20/PCV21 after ≥1 year interval OR PPSV23 after ≥1 year interval 1
• Both PCV13 and PPSV23 (but no PPSV23 at age ≥65) → Give PCV20/PCV21 after ≥5 years from last dose OR give PPSV23 after ≥1 year from PCV13 and ≥5 years from last PPSV23 1

Adults 50-64 Years (Without High-Risk Conditions)

As of October 2024, ACIP expanded recommendations to include all adults ≥50 years:

• Single dose of PCV20, PCV21, or PCV15 + PPSV23 series 2, 3
• This represents a significant change from previous age-based recommendations that started at 65 years 3

Adults 19-49 Years (Only With Risk Factors)

Vaccination indicated ONLY if specific medical conditions present (see below) 1, 2

---

Risk-Based Recommendations (Ages 19-64 Years)

High-Risk Medical Conditions Requiring Vaccination

Chronic conditions:

• Chronic heart disease (including congestive heart failure, cardiomyopathies) 1
• Chronic lung disease (COPD, emphysema, asthma) 1
• Chronic liver disease 1
• Diabetes mellitus 1
• Alcoholism 1
• Cigarette smoking 1

For these conditions:

• Option A: Single dose of PCV20 or PCV21 1
• Option B: PCV15 followed by PPSV23 ≥1 year later 1

---

Immunocompromising Conditions (Ages 19-64 Years)

Conditions Requiring Vaccination with Shorter Intervals

Immunocompromising conditions include:

• Chronic renal failure/nephrotic syndrome 1
• Congenital or acquired asplenia 1
• Sickle cell disease or other hemoglobinopathies 1
• Congenital or acquired immunodeficiencies (B- or T-lymphocyte deficiency, complement deficiencies, phagocytic disorders) 1
• HIV infection 1
• Generalized malignancy, leukemia, lymphoma, Hodgkin disease, multiple myeloma 1
• Solid organ transplant 1
• Iatrogenic immunosuppression (long-term systemic corticosteroids, radiation therapy) 1
• CSF leak 1
• Cochlear implant 1

Vaccination schedule:

Option A:

• Single dose of PCV20 or PCV21 1

Option B:

• PCV15 followed by PPSV23 after ≥8 weeks (NOT ≥1 year as in non-immunocompromised) 1
• If 2 doses of PPSV23 needed: Second PPSV23 dose after ≥5 years from first PPSV23 1

Critical distinction: Immunocompromised patients benefit from the shorter 8-week interval between PCV15 and PPSV23, compared to the 1-year interval for non-immunocompromised adults 1

If previously received PPSV23 only:

• Give PCV20/PCV21 or PCV15 after ≥1 year interval 1

If previously received PCV13 only:

• Give PCV20/PCV21 after ≥1 year interval OR PPSV23 after ≥8 weeks 1
• If giving PPSV23, administer second PPSV23 dose after ≥5 years 1

---

Special Population: Hematopoietic Stem Cell Transplant (HSCT) Recipients

Unique 4-dose schedule starting 3-6 months post-HSCT:

• 3 doses of PCV20 given 4 weeks apart, starting 3-6 months after HSCT 1
• Fourth dose of PCV20 given ≥6 months after third dose OR ≥12 months after HSCT (whichever is later) 1

Alternative if PCV20 unavailable:

• 3 doses of PCV15 (4 weeks apart) followed by single PPSV23 dose ≥1 year after HSCT 1

---

Key Interval Rules

Minimum intervals between vaccines:

• PCV to PPSV23 (immunocompromised/CSF leak/cochlear implant): ≥8 weeks 1
• PCV to PPSV23 (non-immunocompromised): ≥1 year 1
• PPSV23 to PCV: ≥1 year 1
• PCV13 to PCV20/PCV21: ≥1 year 1
• Between PPSV23 doses: ≥5 years 1

---

Common Pitfalls to Avoid

Do not give PPSV23 before PCV in vaccine-naive patients - this reduces the immunogenicity of subsequent PCV doses 1

Do not use 1-year intervals for immunocompromised patients between PCV15 and PPSV23 - these patients benefit from the shorter 8-week interval 1

Do not forget to reassess at age 65 - patients who received vaccines before age 65 for risk conditions may need additional doses at age 65 depending on their vaccination history 1

PCV7-only recipients should be treated as unvaccinated - follow recommendations for vaccine-naive adults 1

Shared decision-making applies only to specific scenarios - primarily for adults ≥65 who already completed PCV13 + PPSV23 at age ≥65 and are considering additional PCV20/PCV21 1